Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

NCT00712426 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00712426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00712426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2009
Completion date
January 31, 2015
Enrollment
553 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

huntington's disease